drugset / Trial / NCT03108833
A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism
RandomizedParallel-groupSingle-blindTreatment
Summary
This trial is being conducted to assess the efficacy and safety of recombinant Human Prourokinase in the acute pulmonary embolism.
Timeline
- Start
- 2017-06-06
- Primary completion
- 2019-12-19
- Completion
- 2019-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alteplase | Protein / enzyme biologic | 1.5 mg/kg | Intravenous |
| Comparator | Alteplase | Protein / enzyme biologic | 100 mg | Intravenous |
| Subject | rhPro-UK | Protein / enzyme biologic | 40 mg | Intravenous |
| Subject | rhPro-UK | Protein / enzyme biologic | 50 mg | Intravenous |